Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Discovering the anti-cancer potential of non-oncology drugs by systematic PRISM profiling

ABSTRACT: Discovering the anti-cancer potential of non-oncology drugs by systematic PRISM profiling

PROVIDER: PRJNA551012 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR9600900_1.fastq.gz	Fastqsanger.gz
	SRR9600900_2.fastq.gz	Fastqsanger.gz
	SRR9600910.fastq.gz	Fastqsanger.gz
	SRR9600901_1.fastq.gz	Fastqsanger.gz
	SRR9600901_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 28

Similar Datasets

Discovering the anti-cancer potential of non-oncology drugs by systematic PRISM profiling

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-08-08 | GSE133299 | GEO

Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.

Project description:Anti-cancer uses of non-oncology drugs have occasionally been found, but such discoveries have been serendipitous. We sought to create a public resource containing the growth inhibitory activity of 4,518 drugs tested across 578 human cancer cell lines. We used PRISM, a molecular barcoding method, to screen drugs against cell lines in pools. An unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines in a manner predictable from the cell lines' molecular features. Our findings include compounds that killed by inducing PDE3A-SLFN12 complex formation; vanadium-containing compounds whose killing depended on the sulfate transporter SLC26A2; the alcohol dependence drug disulfiram, which killed cells with low expression of metallothioneins; and the anti-inflammatory drug tepoxalin, which killed via the multi-drug resistance protein ABCB1. The PRISM drug repurposing resource (https://depmap.org/repurposing) is a starting point to develop new oncology therapeutics, and more rarely, for potential direct clinical translation.

| S-EPMC7328899 | biostudies-literature

Transcriptional profiling of LS1034 cells treated with tepoxalin

Project description:LS1034 colorectal cancer cells were treated with DMSO vehicle control or 12 uM tepoxalin for 6 hours. Anti-cancer uses of non-oncology drugs have been found on occasion, but such discoveries have been serendipitous and rare. To fully discover activity against multiple tumor types, resource-intensive screening across hundreds of cancer cell lines is needed. We sought to create a public resource containing the growth inhibitory activity of 4,518 drugs tested across 578 human cancer cell lines. To accomplish this, we used PRISM, which involves the molecular barcoding of each cell line, followed by pooling of the barcoded lines. Relative barcode abundance following drug treatment versus controls thus reflects cell viability following drug treatment. We found that an unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines. Moreover, the killing activity of the majority of these drugs was predictable based on the molecular features of the cell lines. Mechanistic follow-up of several of these compounds revealed novel mechanisms. These results illustrate the potential of the PRISM drug repurposing resource as a starting point for new oncology therapeutic development.

2019-08-08 | GSE133286 | GEO

Oncology

Project description:Oncology Raw sequence reads

| PRJNA1049638 | ENA

Transcriptional profiling of SF295 cells following MTF1 knockout by CRISPR/Cas9

Project description:SF295 glioblastoma cells were subjected to CRISPR/Cas9-mediated knockout of the MTF1 (metal regulatory transcription factor 1) gene or non-targeted control (GFP). Two guides targeting MTF1 and one guide targeting GFP were cloned into the pXPR_023 all-in-one CRISPR/Cas9 vector. SF295 cells were transduced by lentiviral infection and selected using puromycin. Following selection, RNA was harvested from cell lines growing in culture. Wild-type SF295 cells were also included as a control. Anti-cancer uses of non-oncology drugs have been found on occasion, but such discoveries have been serendipitous and rare. To fully discover activity against multiple tumor types, resource-intensive screening across hundreds of cancer cell lines is needed. We sought to create a public resource containing the growth inhibitory activity of 4,518 drugs tested across 578 human cancer cell lines. To accomplish this, we used PRISM, which involves the molecular barcoding of each cell line, followed by pooling of the barcoded lines. Relative barcode abundance following drug treatment versus controls thus reflects cell viability following drug treatment. We found that an unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines. Moreover, the killing activity of the majority of these drugs was predictable based on the molecular features of the cell lines. Mechanistic follow-up of several of these compounds revealed novel mechanisms. These results illustrate the potential of the PRISM drug repurposing resource as a starting point for new oncology therapeutic development.

2019-08-08 | GSE133285 | GEO

Patient-derived micro-organospheres (MOS) enable clinical precision oncology

Project description:Patient-derived xenografts (PDX) and organoids (PDO) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of Micro- Organospheres (MOS) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of newly diagnosed metastatic colorectal cancer (CRC) patients using a MOS-based precision oncology pipeline reliably predicted patient treatment outcome within 14 days, a timeline suitable for guiding treatment decisions in clinic. Furthermore, MOS capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.

2022-09-01 | GSE184242 | GEO

Application of selective internal radiotherapy with yttrium-90 microspheres combined with systematic therapy in preoperative transformation therapy of potential resectable colorectal cancer with liver metastasis

Project description:Interventions: A:selective internal radiotherapy with yttrium-90 microspheres combined with systematic therapy;B:systematic therapy Primary outcome(s): Objective response rate, ORR;Surgical conversion rate;Recurrence free survival, PFS Study Design: Non randomized control

| 86433 | ecrin-mdr-crc

Expression Project for Oncology (expO)

Project description:The mission of expO is to build on the technologies and outcomes of the Human Genome Project to accelerate improved clinical management of cancer patients. IGC's Expression Project for Oncology (expO) seeks to integrate longitudinal clinical annotation with gene expression data for a unique and powerful portrait of human malignancies, providing critical perspective on diagnostic markers, prognostic indicators, and therapeutic targets. The goal of expO and its consortium supporters is to procure tissue samples under standard conditions and perform gene expression analyses on a clinically annotated set of deidentified tumor samples. The tumor data is updated with clinical outcomes and is released into the public domain without intellectual property restriction. Series-matrices are available at ftp://ftp.ncbi.nlm.nih.gov/pub/geo/DATA/SeriesMatrix/GSE2109/. For more information, see http://www.intgen.org/ Keywords: cancer portraits

2005-01-15 | E-GEOD-2109 | biostudies-arrayexpress

CPTAC: Microscaled Proteogenomic Methods for Precision Oncology

Project description:CPTAC: Microscaled Proteogenomic Methods for Precision Oncology

| PRJNA574689 | ENA

Assessment of Spatial Genomics for Oncology Discovery

Project description:Assessment of Spatial Genomics for Oncology Discovery

| PRJNA872761 | ENA